Anti-tuberculosis prophylaxis following renal transplantation: acceptable variations?

Area of Science:

• Nephrology
• Infectious Disease
• Pharmacology

Background:

• Current guidelines recommend tuberculosis (TB) prophylaxis for renal transplant recipients from endemic areas or at-risk individuals.
• Concerns exist that existing guidelines may not sufficiently protect all at-risk transplant patients.
• This study investigated variations in TB prophylaxis policies across UK renal transplant centers.

Purpose of the Study:

• To identify and quantify the variations in tuberculosis (TB) prophylaxis strategies among different renal transplant units in the United Kingdom.
• To assess the consistency of TB prophylaxis policies and patient selection criteria in post-renal transplant care.

Main Methods:

• A survey was conducted among renal pharmacists at all 25 UK renal transplant centers.
• Data collected included specific drug prophylaxis, treatment duration, and eligibility criteria for prophylaxis.
• A 96% response rate (24/25 centers) was achieved.

Main Results:

• Significant variation in TB prophylaxis regimens was observed, ranging from no prophylaxis to lifelong isoniazid.
• The most common treatment duration was 6 months post-transplantation.
• Discrepancies were noted in the concurrent use of pyridoxine and in the criteria for determining which patients receive prophylaxis, independent of regional TB incidence.

Conclusions:

• A substantial discrepancy exists in the pharmacological prophylaxis for tuberculosis (TB) among UK renal transplant units.
• There is also marked variation in the selection of individuals who should receive TB prophylaxis treatment.